Last reviewed · How we verify
Carbidopa Low-Dose
Carbidopa is a decarboxylase inhibitor that prevents the conversion of levodopa to dopamine, thereby increasing the availability of levodopa in the brain.
Carbidopa is a decarboxylase inhibitor that prevents the conversion of levodopa to dopamine, thereby increasing the availability of levodopa in the brain. Used for Parkinson's disease.
At a glance
| Generic name | Carbidopa Low-Dose |
|---|---|
| Also known as | Lodosyn ®, DL-α-methyl-α-hydrazino-3, 4-dihydroxyphenyl-propionic acid, HMD, MK-486 |
| Sponsor | NYU Langone Health |
| Drug class | Aromatic L-amino acid decarboxylase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the enzyme aromatic L-amino acid decarboxylase, carbidopa increases the levels of levodopa in the brain, allowing for more effective treatment of Parkinson's disease symptoms. This is particularly useful in low-dose formulations, where the goal is to minimize side effects while maintaining therapeutic efficacy.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
Key clinical trials
- Dose Ranging Study of Carbidopa-levodopa (PHASE2)
- Effects of 5HTP on the Injured Human Spinal Cord (PHASE2, PHASE3)
- Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics (PHASE3)
- A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients (PHASE1)
- A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) (PHASE3)
- Carbidopa for the Treatment of Excessive Blood Pressure Variability (PHASE2)
- High and Low Dose Carbidopa Treatment of Parkinson's Disease (PHASE2)
- A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |